Satsuma Pharmaceutic (STSA)

[muneeflo]

For Satsuma Pharmaceuticals Inc (NASDAQ:STSA), Mizuho downgraded the previous rating of Buy to the current rating Neutral. In the second quarter, Satsuma Pharmaceuticals earned $0.65. The stock has a 52-week-high of $36.10 and a 52-week-low of $4.55. At the end of the last trading period, Satsuma Pharmaceuticals closed at $5.62.

For Satsuma Pharmaceuticals Inc (NASDAQ:STSA), Credit Suisse downgraded the previous rating of Outperform to the current rating Underperform. In the second quarter, Satsuma Pharmaceuticals earned $0.65. At the moment, the stock has a 52-week-high of $36.10 and a 52-week-low of $4.55. Satsuma Pharmaceuticals closed at $5.62 at the end of the last trading period.